

intravenous, and topical means.

8. The method of Claim 6, where said administering step is comprised of administering the composition by a means selected from the group consisting of oral, intraperitoneal, intravenous, and topical means.

9. A method of inhibiting skin cancer in a mammal, comprising the step of administering to the mammal in need of treatment for inhibition of skin cancer a composition comprised of a hydrolysis product of sericin.

11 10. The method of Claim 9, wherein the weight average molecular weight of said hydrolysis product of sericin is from 5,000 to 100,000.

11. The method of Claim 9, where said administering step is comprised of administering the composition by a means selected from the group consisting of oral, intraperitoneal, intravenous, and topical means.

12. The method of Claim 10, where said administering step is comprised of administering the composition by a means selected from the group consisting of oral, intraperitoneal, intravenous, and topical means.

REMARKS

This is a full and timely response to the Office Action dated November 20, 2002.

Reexamination and reconsideration in light of the following remarks are courteously requested.

The application includes claims 5 to 12, which are method claims directed to methods of inhibiting skin cancer. Prior to the amendment, claim 5 recited: